




Instance: composition-en-ed982183c35912e878ca478e2f38304e
InstanceOf: CompositionUvEpi
Title: "Composition for cerdelga Package Leaflet"
Description:  "Composition for cerdelga Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mped982183c35912e878ca478e2f38304e)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - cerdelga"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Cerdelga is and what it is used for  </li>
<li>What you need to know before you take Cerdelga </li>
<li>How to take Cerdelga  </li>
<li>Possible side effects  </li>
<li>How to store Cerdelga  </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What cerdelga is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What cerdelga is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Cerdelga contains the active substance eliglustat and is used for the long term treatment of adult 
patients with Gaucher disease type 1. Gaucher disease type 1 is a rare, inherited condition in which a substance called glucosylceramide is 
not effectively broken down by your body. As a result glucosylceramide builds up in your spleen, liver 
and bones. The build-up prevents these organs from working properly. Cerdelga contains the active 
substance eliglustat which decreases the production of glucosylceramide, thereby preventing its build-
up. In turn this helps your affected organs to work better. </p>
<p>People differ in the speed that their body breaks down this medicine. As a result the amount of this 
medicine in the blood can differ between patients which could affect how a patient would respond. 
Cerdelga is meant to be used in patients whose body breaks down this medicine at normal speed 
(known as intermediate metabolisers and extensive metabolisers) or slow speed (known as poor 
metabolisers). Your doctor will determine if Cerdelga is suitable for you before you start taking it, 
using a simple laboratory test. </p>
<p>Gaucher disease type 1 is a lifelong condition and you must continue to take this medicine as 
prescribed by your doctor to gain the maximum benefit from your medicine. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take cerdelga"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take cerdelga"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Cerdelga 
- If you are allergic to eliglustat or any of the other ingredients of this medicine (listed in 
section 6). 
- If you are an intermediate or extensive metaboliser and use medicines  known as strong or 
moderate CYP2D6 inhibitors (examples are quinidine and terbinafine) used in combination 
with strong or moderate CYP3A inhibitors (examples are erythromycin and itraconazole). The 
combination of these medicines will interfere with your body s ability to break down Cerdelga 
and this can result in higher levels of the active substance in your blood (see the section  Other 
medicines and Cerdelga  for an expanded list of medicines). 
- If you are a poor metaboliser and use medicines known as strong CYP3A inhibitors (for 
example itraconazole). Medicines of this type will interfere with your body s abilty to break 
down Cerdelga and this can result in higher levels of the active substance in your blood (see 
the section  Other medicines and Cerdelga  for an expanded list of medicines). 
- If you are an extensive metaboliser and you have severely reduced liver function. 
- If you are an extensive metaboliser and you have mildly or moderately reduced liver function 
while taking a strong or moderate CYP2D6 inhibitor. </p>
<p>Warnings and precautions<br />
Talk to your doctor or pharmacist before taking Cerdelga, if you: 
*  are currently treated, or about to start treatment with any of the medicines listed in section 
 Other medicines and Cerdelga.<br />
<em> have had a heart attack or heart failure. 
* have a slow heart rate. 
* have an irregular, or abnormal heart beat, inluding a heart condition called long QT syndrome. 
* have any other heart problems. 
* are taking an antiarrhythmic medicine (used to treat irregular heart beat) like quinidine, 
amiodarone or sotalol. 
* are an extensive metaboliser and you have moderately reduced liver function. 
* are an intermediate or poor metaboliser and you have any level of reduced liver function. 
* are an intermediate or poor metaboliser and you have reduced kidney function.<br />
</em> are an end stage renal disease (ESRD) patient. </p>
<p>Children and adolescents 
Cerdelga has not been tested in children and adolescents under 18 years of age. Do not give this 
medicine to children or adolescents. </p>
<p>Other medicines and Cerdelga 
Please tell your doctor or pharmacist if you are using, or have recently used, or might use, any other 
medicines. </p>
<p>Medicines that must not be taken in combination with each other and Cerdelga 
Cerdelga must not be used with certain type of medicines. These medicines can interfere with your 
body s ability to break down Cerdelga and this can result in higher levels of Cerdelga in your blood. 
These medicines are known as strong or moderate CYP2D6 inhibitors and strong or moderate CYP3A 
inhibitors. There are many medicines in these categories and depending on how your body breaks 
down Cerdelga the effects may differ from person to person. Please speak to your doctor regarding 
these medicines before you start taking Cerdelga. Your doctor will determine which medicines you 
can use based on how fast your body breaks down eliglustat. </p>
<p>Medicines that may increase the level of Cerdelga in the blood such as: 
* paroxetine, fluoxetine, fluvoxamine, duloxetine, bupropion, moclobemide   antidepressants 
(used to treat depression) 
* dronedarone, quinidine, verapamil   antiarrhythmic medicines (used to treat irregular 
heartbeat) 
* ciprofloxacin, clarithromycin, erythromycin, telithromycin   antibiotics (used to treat 
infections) 
* terbinafine, itraconazole, fluconazole, posaconazole, voriconazole   antifungals (used to treat 
fungal infections) 
* mirabegron   used to treat overactive bladders 
* cinacalcet   calcimimetic (used in some dialysis patients and specific cancers) 
* atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, ritonavir, saquinavir, tipranavir <br />
antiretrovirals (used to treat HIV) 
* cobicistat   used to improve the effects of antiretrovirals (used to treat HIV) 
* aprepitant   antiemetic (used to reduce vomiting) 
* diltiazem   antihypertensive (used to increase blood flow and decrease heart rate) 
* conivaptan   diuretic (used to increase low blood sodium levels) 
* boceprevir, telaprevir   antiviral (used to treat Hepatitis C) 
* imatinib   anticancer (used to treat cancer) 
* amlopidine, ranolazine     used to treat angina pectoris<br />
* cilostazol   used to treat cramp-like pain in your legs when you walk caused by insufficient 
blood supply in your legs 
* isoniazid   used to treat tuberculosis. 
* cimetidine, ranitidine   antacids (used to treat indigestion) 
* goldenseal   (also known as Hydrastis canadensis) a herbal preparation obtained without a 
prescription, used as a digestive aid. </p>
<p>Medicines that may decrease the level of Cerdelga in the blood: 
* rifampicin, rifabutin   antibiotics (used to treat infections) 
* carbamazepine, phenobarbital, phenytoin  anti-epileptics (used to treat epilepsy and seizures) 
* St. John s wort   (also known as Hypericum perforatum) a herbal preparation obtained 
without a prescription, used to treat depression and other conditions  </p>
<p>Cerdelga may increase the level of the following types of medicines in the blood: 
* dabigatran   anticoagulant (used to thin the blood) 
* phenytoin   anti-epileptic (used to treat epilepsy and seizures) 
* nortryptyline, amitriptyline, imipramine, desipramine   antidepressants (used to treat 
depression) 
* phenothiazines   antipsychotics (used to treat schizophrenia and psychosis) 
* digoxin  used to treat heart failure and atrial fibrillation 
* colchicine   used to treat gout 
* metoprolol   used to lower blood pressure and/or reduce heart rate 
* dextromethorphan   cough medicine 
* atomoxetine   used to treat attention deficit hyperactivity disorder (ADHD) 
* pravastatin   used to lower cholesterol and prevent heart disease </p>
<p>Taking Cerdelga with food and drink 
Avoid consumption of grapefruit or grapefruit juice since it may increase the level of Cerdelga in your 
blood. </p>
<p>Pregnancy, breast-feeding and fertility 
If you are pregnant, think that you may be pregnant or are planning to have a baby, tell your doctor 
who will discuss with you whether you can take this medicine during your pregnancy. </p>
<p>The active substance in this medicine has been shown to pass in trace amounts into breast milk in 
animals. Breast-feeding is not recommended during treatment with this medicine. Tell your doctor if 
you are breast-feeding. </p>
<p>There are no known effects on fertility at normal doses. </p>
<p>Driving and using machines 
Cerdelga has negligible or no influence on the ability to drive and use machines. </p>
<p>Cerdelga contains lactose<br />
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor 
before taking this medicine. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take cerdelga"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take cerdelga"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure.  </p>
<p>If you are an intermediate metaboliser or extensive metaboliser: 
Swallow one 84 mg capsule whole twice a day with water. It may be taken with or without food. Take 
one capsule in the morning and one capsule at night.  </p>
<p>If you are a poor metaboliser: 
Swallow one 84 mg capsule whole once a day with water. It may be taken with or without food. Take 
one capsule at the same time every day.  </p>
<p>Do not open, crush, dissolve, or chew the capsule before swallowing it. If you cannot swallow the 
capsule whole, tell your doctor. </p>
<p>Continue taking Cerdelga every day for as long as your doctor tells you. </p>
<p>How to pull the blister/wallet from the sleeve 
While pressing your thumb and finger together at one end of the sleeve (1) gently pull the 
blister/wallet out to open the sleeve (2). </p>
<p>If you take more Cerdelga than you should 
If you take more capsules than you were told to, consult your doctor immediately. You may 
experience dizziness marked by loss of balance, slow heart rate, nausea, vomiting and light-
headedness. </p>
<p>If you forget to take Cerdelga 
Take the next capsule at the usual time. Do not take a double dose to make up for a forgotten dose. </p>
<p>If you stop taking Cerdelga 
Do not stop taking Cerdelga without talking to your doctor.  </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.  </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.  </p>
<p>Common (may affect up to 1 in 10 people): 
* Headache 
* Dizziness 
* Change in taste (dysgeusia) 
* Palpitations 
* Throat irritation 
* Cough 
* Heartburn (dyspepsia) 
* Feeling sick (nausea) 
* Diarrhoea 
* Constipation 
* Abdominal pain 
* Stomach ache (upper abdominal pain) 
* Acid reflux disease (gastrooesophageal reflux disease) 
* Bloating (abdominal distension) 
* Inflammation of the stomach (gastritis) 
* Difficulty swallowing (dysphagia) 
* Vomiting 
* Dry mouth 
* Gas (flatulence) 
* Dry skin 
* Hives (urticaria) 
* Joint pain (arthalagia) 
* Pain in arms, legs or back 
* Tiredness (fatigue) </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store cerdelga"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store cerdelga"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton, sleeve and blister after 
 EXP . The expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions.  </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Cerdelga contains<br />
* The active substance is eliglustat (as tartrate). Each capsule contains 84 mg eliglustat. 
* The other ingredients are:  * In the capsule: microcrystalline cellulose, lactose monohydrate (see section 2 under 
 Cerdelga contains lactose ), hypromellose and glycerol dibehenate. * In the capsule shell: gelatin, potassium aluminium silicate (E555), titanium dioxide 
(E171), yellow iron oxide (E172) and indigotine (E132). * In the printing ink: shellac, black iron oxide (E172), propylene glycol and ammonia 
solution, concentrated. </p>
<p>What Cerdelga looks like and contents of the pack 
Cerdelga capsules have a pearl blue-green opaque cap and a pearl white opaque body with  GZ02<br />
printed in black on the capsule. </p>
<p>Pack sizes of 14 hard capsules in 1 blister wallet, 56 hard capsules in 4 blister wallets of 14 capsules 
each or 196 hard capsules in 14 blister wallets of 14 capsules each  </p>
<p>Not all packs may be marketed in your country. </p>
<p>Marketing Authorisation Holder<br />
Sanofi B.V. 
Paasheuvelweg 1105 BP Amsterdam 
The Netherlands 
Manufacturer 
Sanofi Winthrop Industrie 
30-36 avenue Gustave Eiffel 
37100 Tours 
France </p>
<p>Sanofi Winthrop Industrie 
1 rue de la Vierge 
Ambares et Lagrave 
33565 Carbon Blanc cedex 
France </p>
<p>Genzyme Ireland Ltd 
IDA Industrial Park<br />
Old Kilmeaden Road<br />
Waterford 
Ireland </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien/ 
Luxembourg/Luxemburg 
Sanofi Belgium 
T l/Tel: + 32 2 710 54 Lietuva 
Swixx Biopharma UAB 
Tel: +370 5 236 91 <br />
Swixx Biopharma EOOD 
 .: +359 (0)2 4942 Magyarorsz g 
SANOFI-AVENTIS Zrt. 
Tel: +36 1 505 0 esk  republika 
sanofi-aventis, s.r.o. 
Tel: +420 233 086 Malta 
Sanofi S.r.l. 
Tel: +39 02 39394Danmark 
Sanofi A/S 
Tlf: +45 45 16 70 Nederland 
Sanofi B.V. 
Tel: +31 20 245 4Deutschland 
Sanofi-Aventis Deutschland GmbH 
Tel.: 0800 04 36 Tel. aus dem Ausland: +49 69 305 70 Norge 
sanofi-aventis Norge AS 
Tlf: + 47 67 10 71 Eesti 
Swixx Biopharma O <br />
Tel: +372 640 10  sterreich 
sanofi-aventis GmbH 
Tel: + 43 1 80 185 - 0 </p>
<p>Sanofi-Aventis   AEBE 
 : +30 210 900 1Polska 
sanofi-aventis Sp. z o.o. 
Tel.: +48 22 280 00 Espa a 
sanofi-aventis, S.A. 
Tel: +34 93 485 94 Portugal 
Sanofi   Produtos Farmac uticos, Lda. 
Tel: +351 21 35 89 France 
Sanofi Winthrop Industrie<br />
T l: 0 800 222 Appel depuis l tranger: +33 1 57 63 23 Rom nia 
Sanofi Romania SRL 
Tel: +40 (0) 21 317 31 Hrvatska 
Swixx Biopharma d.o.o. 
Tel: +385 1 2078 Slovenija 
Swixx Biopharma d.o.o.<br />
Tel: +386 1 235 51 Ireland 
sanofi-aventis Ireland Ltd. T/A SANOFI 
Tel: +353 (0) 1 403 56  sland 
Vistor hf. 
S mi: +354 535 7Slovensk  republika 
Swixx Biopharma s.r.o. 
Tel: +421 2 208 33 Italia 
Sanofi S.r.l. 
Tel: 800 536 Suomi/Finland 
Sanofi Oy 
Puh/Tel: + 358 201 200 <br />
C.A. Papaellinas Ltd. 
 : +357 22 741Sverige 
Sanofi AB 
Tel: +46 (0)8 634 50 Latvija 
Swixx Biopharma SIA<br />
Tel: +371 6 616 47 United Kingdom (Northern Ireland) 
sanofi-aventis Ireland Ltd. T/A SANOFI 
Tel: +44 (0) 800 035 2This leaflet was last revised in  </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-ed982183c35912e878ca478e2f38304e
InstanceOf: CompositionUvEpi
Title: "Composition for cerdelga Package Leaflet"
Description:  "Composition for cerdelga Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mped982183c35912e878ca478e2f38304e)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - cerdelga"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse af Cerdelga 
2. Det skal du vide, før du begynder at tage Cerdelga 
3. Sådan skal du tage Cerdelga<br />
4. Bivirkninger<br />
5. Opbevaring af Cerdelga<br />
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What cerdelga is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What cerdelga is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Cerdelga indeholder det aktive stof eliglustat og anvendes til langtidsbehandling af voksne patienter 
med Gauchers sygdom type 1. Gauchers sygdom type 1 er en sjælden, arvelig sygdom, hvor et stof betegnet glucosylceramid ikke 
nedbrydes af kroppen på effektiv vis. Som følge heraf hober glucosylceramid sig op i milten, leveren 
og knoglerne. Denne ophobning forhindrer disse organer i at fungere korrekt. Cerdelga indeholder det 
aktive stof eliglustat der nedsætter produktionen af glucosylceramid, hvilket forhindrer ophobning. 
Som følge her af hjælper det dine berørte organer med at fungere bedre. </p>
<p>Forskellige mennesker nedbryder dette lægemiddel ved forskellige hastigheder i kroppen. Mængden af 
medicin i blodet kan derfor variere patienterne imellem, hvilket kan påvirke, hvordan en patient vil 
reagere. Cerdelga er beregnet til at blive brugt til patienter, hvis krop nedbryder lægemidlet ved 
normal hastighed (kaldet intermediære metabolisatorer og ekstensive metabolisatorer) eller langsom 
hastighed (kaldet langsomme metabolisatorer). Din læge vil ved hjælp af en simpel laboratorietest 
afgøre, om Cerdelga er velegnet til dig, før du begynder at tage det. </p>
<p>Gauchers sygdom type 1 er en livslang sygdom, og du skal fortsætte med at tage dette lægemiddel som 
ordineret af din læge for at få det maksimale udbytte af din medicin. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take cerdelga"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take cerdelga"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Cerdelga:</p>
<ul>
<li>hvis du er allergisk over for eliglustat eller et af de øvrige indholdsstoffer i Cerdelga (angivet i 
punkt 6). </li>
<li>hvis du er en intermediær eller ekstensiv metabolisator, og bruger lægemidler, der er kendt 
under betegnelsen potente eller moderate CYP2D6-hæmmere (eksempler er quinidin og 
terbinafin), der anvendes i kombination med potente eller moderate CYP3A-hæmmere 
(eksempler er erythromycin og itraconazol). Kombinationen af disse lægemidler vil forstyrre din 
krops evne til at nedbryde Cerdelga, og dette kan resultere i højere niveauer af det aktive stof i 
blodet (se afsnittet "Anden medicin og Cerdelga" for en udvidet liste over lægemidler). </li>
<li>Hvis du er en langsom metabolisator, og bruger medicin, der kaldes potente CYP3A-hæmmere 
(for eksempel itraconazol). Denne type medicin vil forstyrre din krops evne til at nedbryde 
Cerdelga, og det kan resultere i højere niveauer af det aktive stof i dit blod (se afsnittet “Brug af 
anden medicin sammen med Cerdelga" for en udvidet medicinliste). </li>
<li>Hvis du er en ekstensiv metabolisator, og du har alvorlig nedsat leverfunktion. </li>
<li>Hvis du er en ekstensiv metabolisator, og du har let eller moderat nedsat leverfunktion, samtidig 
med at du tager en stærk eller moderat CYP2D6-hæmmer. </li>
</ul>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du tager Cerdelga, hvis du: 
 
i øjeblikket behandles eller er ved at starte behandling med et af de lægemidler, der er anført i 
afsnittet "Anden medicin og Cerdelga". 
 
har haft et hjerteanfald eller hjertesvigt. 
 
har en langsom hjertefrekvens. 
 
har en uregelmæssig eller unormal hjerterytme, inklusive en hjertesygdom betegnet langt QT-
syndrom. 
 
har andre hjerteproblemer. 
 
tager antiarytmika (der anvendes til at behandle uregelmæssig hjerterytme) såsom quinidin, 
amiodaron eller sotalol. 
 
er en ekstensiv metabolisator, og du har moderat nedsat leverfunktion. 
 
er en intermediær eller en langsom metabolisator, og du har nogen form for nedsat 
leverfunktion. 
 
er en intermediær eller en langsom metabolisator, og du har nedsat nyrefunktion. 
 
er en patient med nyresygdom i slutstadiet (ESRD). </p>
<p>Børn og unge 
Cerdelga er ikke blevet testet hos børn og unge under 18 år. Dette lægemiddel må ikke gives til børn 
og unge. </p>
<p>Brug af anden medicin sammen med Cerdelga 
Fortæl altid lægen eller apotekspersonalet, hvis du bruger anden medicin eller har gjort det for nylig. </p>
<p>Lægemidler, der ikke må tages i kombination med hinanden og Cerdelga 
Cerdelga må ikke tages sammen med visse typer medicin. Disse lægemidler kan forstyrre din krops 
evne til at nedbryde Cerdelga, og dette kan resultere i højere niveauer af Cerdelga i blodet. Disse 
lægemidler er kendt som potente eller moderate CYP2D6-hæmmere og potente eller moderate 
CYP3A-hæmmere. Der er mange slags medicin i disse kategorier, og afhængigt af hvordan din krop 
nedbryder Cerdelga, kan virkningen være forskellig fra den ene person til den anden. Tal med din læge 
om disse lægemidler, før du begynder at tage Cerdelga. Din læge vil afgøre, hvilken medicin du kan 
bruge, baseret på hvor hurtigt din krop nedbryder eliglustat. </p>
<p>Lægemidler, der kan øge mængden af Cerdelga i blodet, såsom: 
 
paroxetin, fluoxetin, fluvoxamin, duloxetin, bupropion, moclobemid - antidepressiva (bruges 
til at behandle depression) 
 
dronedaron, quinidin, verapamil - antiarytmika (bruges til at behandle en uregelmæssig 
hjerterytme) 
 
ciprofloxacin, clarithromycin, erythromycin, telithromycin - antibiotika (bruges til at behandle 
infektioner) 
 
terbinafin, itraconazol, fluconazol, posaconazol, voriconazol - antisvampemidler (bruges til at 
behandle svampeinfektioner) 
 
mirabegron - bruges til at behandle overaktive blærer 
 
cinacalcet - calcimimetikum (bruges hos nogle dialysepatienter og til bestemte kræftformer) 
 
atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, ritonavir, saquinavir, tipranavir - 
antiretrovirale lægemidler (bruges til at behandle HIV) 
 
cobistat - bruges til at forbedre virkningen af antiretrovirale lægemidler (bruges til at behandle 
HIV) 
 
aprepitant - antiemetika (bruges til at reducere opkastning) 
 
diltiazem - antihypertensive lægemidler (bruges til at øge blodgennemstrømningen og sænke 
hjertefrekvensen) 
 
conivaptan - diuretika (bruges til at øge et lavt indhold af natrium i blodet) 
 
boceprevir, telaprevir - antiretroviralt lægemiddel (bruges til at behandle hepatitis C) 
 
imatinib - anticancer (bruges til at behandle cancer) 
 
amlodipin, ranolazin - bruges til at behandle angina pectoris 
 
cilostazol - bruges til at behandle krampelignende smerter i dine ben, når du går, pga. 
utilstrækkelig blodforsyning i dine ben 
 
isoniazid - bruges til at behandle tuberkulose 
 
cimetidin, ranitidin - antacida (bruges til at behandle fordøjelsesbesvær) 
 
gyldensegl- (også kaldet Hydrastis canadensis) en urtemedicin der kan fås uden recept, bruges 
som hjælp til fordøjelsen. </p>
<p>Lægemidler, der kan reducere mængden af Cerdelga i blodet: 
 
rifampicin, rifabutin - antibiotika (bruges til at behandle infektioner) 
 
carbamazepin, phenobarbital, phenytoin -anti-epileptika (bruges til at behandle epilepsi og 
anfald) 
 
Perikum - (også kendt som Hypericum perforatum) et naturlægemiddel, der kan købes uden 
recept og anvendes til at behandle depression og andre sygdomme  </p>
<p>Cerdelga kan øge mængden af følgende typer medicin i blodet: 
 
dabigatran - antikoagulans (bruges til at fortynde blodet) 
 
phenytoin - anti-epileptika (bruges til at behandle epilepsi og anfald) 
 
nortryptylin, amitriptylin, imipramin, desipramin - antidepressiva (bruges til at behandle 
depression) 
 
phenothiaziner - antipsykotika (bruges til at behandle skizofreni og psykose) 
 
digoxin - bruges til at behandle hjertesvigt og atrieflimren 
 
colchicin - bruges til at behandle gigt 
 
metoprolol - bruges til at sænke blodtrykket og/eller mindske hjertefrekvensen 
 
dextromethorphan - hostemedicin 
 
atomoxetin - bruges til at behandle attention deficit hyperactivity disorder (ADHD) 
 
pravastatin - bruges til at sænke kolesteroltallet og forebygge hjertesygdom </p>
<p>Brug af Cerdelga sammen med mad og drikke 
Undgå indtagelse af grapefrugt eller grapefrugtjuice, da det kan øge indholdet af Cerdelga i blodet. </p>
<p>Graviditet, amning og frugtbarhed 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel under graviditeten. </p>
<p>Det aktive stof i dette lægemiddel er påvist at udskilles i meget små mængder i modermælken hos dyr. 
Det frarådes at amme under behandlingen med dette lægemiddel. Fortæl din læge, hvis du ammer. </p>
<p>Der er ingen kendte virkninger på frugtbarhed ved normale doser. </p>
<p>Trafik- og arbejdssikkerhed 
Cerdelga påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj og betjene maskiner. </p>
<p>Cerdelga indeholder laktose<br />
Hvis du har fået at vide af lægen, at du ikke tåler visse sukkerarter, skal du kontakte lægen, før du 
tager dette lægemiddel. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take cerdelga"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take cerdelga"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller på apoteket.  </p>
<p>Hvis du er en intermediær metabolisator eller ekstensiv metabolisator: 
Slug én 84 mg kapsel hel to gange om dagen med vand. Den kan tages med eller uden et måltid. Tag 
en kapsel om morgenen og en kapsel om aftenen.  </p>
<p>Hvis du er en langsom metabolisator: 
Slug én 84 mg kapsel hel en gang om dagen med vand. Den kan tages med eller uden et måltid. Tag en 
kapsel på samme tid hver dag. </p>
<p>Kapslen må ikke åbnes, knuses, opløses eller tygges, før den sluges. Hvis du ikke kan sluge kapslen 
hel, skal du fortælle det til din læge.  </p>
<p>Fortsæt med at tage Cerdelga hver dag, så længe lægen beder dig om det. </p>
<p>Sådan trækkes blisterpakken/kortet ud af hylsteret. 
Mens du trykker tommelfingeren og en finger sammen i den ene ende af hylsteret (1), trækker 
du forsigtigt blisterpakken/kortet ud for at åbne hylsteret (2). </p>
<p>Hvis du har taget for meget Cerdelga 
Hvis du tager flere kapsler, end du blev anvist, skal du straks kontakte din læge. Du kan opleve 
svimmelhed med tab af balance, langsom puls, kvalme, opkastning og uklarhed. </p>
<p>Hvis du har glemt at tage Cerdelga 
Tag den næste kapsel på det sædvanlige tidspunkt. Du må ikke tage en dobbeltdosis som erstatning for 
den glemte dosis. </p>
<p>Hvis du holder op med at tage Cerdelga 
Hold ikke op med at tage Cerdelga uden at tale med din læge.  </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om.  </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Almindelig (kan påvirke op til 1 ud af 10 personer): 
 
Hovedpine 
 
Svimmelhed 
 
Smagsforstyrrelser (dysgeusi)<br />
 
Hjertebanken 
 
Halsirritation 
 
Hoste 
 
Sure opstød/halsbrand 
 
Utilpashed (kvalme) 
 
Diarré 
 
Forstoppelse 
 
Mavesmerter 
 
Mavepine (øvre mavesmerter) 
 
Sure opstød (gastroesofageal reflukssygdom) 
 
Oppustethed (abdominal udspiling) 
 
Mavekatar (gastritis) 
 
Synkebesvær (dysfagi) 
 
Opkastning 
 
Mundtørhed 
 
Tarmluft (flatulens) 
 
Tør hud 
 
Nældefeber (urticaria) 
 
Ledsmerter (artralgi) 
 
Smerter i arme, ben eller ryg 
 
Træthed </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, sygeplejerske eller apoteket.<br />
Dette gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine 
pårørende kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale 
rapporteringssystem anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at 
fremskaffe mere information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store cerdelga"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store cerdelga"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på pakningen efter Exp. Udløbsdatoen er den 
sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen.  </p>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Cerdelga indeholder:<br />
 
Aktivt stof: eliglustat (som tartrat). Hver kapsel indeholder 84 mg eliglustat. 
 
Øvrige indholdsstoffer:  * 
I kapslen: mikrokrystallinsk cellulose, laktosemonohydrat (se punkt 2 under "Cerdelga 
indeholder laktose"), hypromellose og glyceroldibehenat. * 
I kapslens skal: gelatine, kaliumaluminiumsilikat (E555), titandioxid (E171), gul jernoxid 
(E172) og indigotin (E132). * 
I trykfarven: schellak, sort jernoxid (E172), propylenglycol og ammoniakopløsning, 
koncentreret. </p>
<p>Udseende og pakningsstørrelser 
Cerdelga-kapsler har en perlemors-blågrøn uigennemsigtig hætte og perlehvid uigennemsigtig krop 
med "GZ02" trykt i sort på kapslen. </p>
<p>Pakningsstørrelser med 14 hårde kapsler i 1 blisterkort, 56 hårde kapsler i 4 blisterkort med 14 kapsler 
i hver eller 196 hårde kapsler i 14 blisterkort med 14 kapsler i hver. </p>
<p>Det er ikke sikkert, at alle pakninger markedsføres i dit land. </p>
<p>Indehaver af markedsføringstilladelsen<br />
Sanofi B.V. 
Paasheuvelweg 25<br />
1105 BP Amsterdam 
Holland </p>
<p>Fremstiller 
Sanofi Winthrop Industrie 
30-36 avenue Gustave Eiffel 
37100 Tours 
Frankrig </p>
<p>Sanofi Winthrop Industrie 
1 rue de la Vierge 
Ambares et Lagrave 
33565 Carbon Blanc cedex 
Frankrig 
Genzyme Ireland Ltd 
IDA Industrial Park<br />
Old Kilmeaden Road<br />
Waterford 
Irland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien/ 
Luxembourg/Luxemburg 
Sanofi Belgium 
Tél/Tel: + 32 2 710 54<br />
Lietuva 
Swixx Biopharma UAB 
Tel: +370 5 236 91<br />
България 
Swixx Biopharma EOOD 
Тел.: +359 (0)2 4942 Magyarország 
SANOFI-AVENTIS Zrt. 
Tel: +36 1 505 0 </p>
<p>Česká republika 
sanofi-aventis, s.r.o. 
Tel: +420 233 086<br />
Malta 
Sanofi S.r.l. 
Tel: +39 02 39394 
Danmark 
Sanofi A/S 
Tlf: +45 45 16 70<br />
Nederland 
Sanofi B.V. 
Tel: +31 20 245 4Deutschland 
Sanofi-Aventis Deutschland GmbH 
Tel.: 0800 04 36 Tel. aus dem Ausland: +49 69 305 70<br />
Norge 
sanofi-aventis Norge AS 
Tlf: + 47 67 10 71<br />
Eesti 
Swixx Biopharma OÜ<br />
Tel: +372 640 10 <br />
Österreich 
sanofi-aventis GmbH 
Tel: + 43 1 80 185 - 0 
Ελλάδα 
Sanofi-Aventis Μονοπρόσωπη AEBE 
Τηλ: +30 210 900 1 </p>
<p>Κύπρος 
C.A. Papaellinas Ltd. 
Τηλ: +357 22 741 
Polska 
sanofi-aventis Sp. z o.o. 
Tel.: +48 22 280 00<br />
España 
sanofi-aventis, S.A. 
Tel: +34 93 485 94 <br />
Portugal 
Sanofi - Produtos Farmacêuticos, Lda. 
Tel: +351 21 35 89<br />
France 
Sanofi Winthrop Industrie 
Tél: 0 800 222 Appel depuis l’étranger: +33 1 57 63 23<br />
România 
Sanofi Romania SRL 
Tel: +40 (0) 21 317 31<br />
Hrvatska 
Swixx Biopharma d.o.o. 
Tel: +385 1 2078<br />
Slovenija 
Swixx Biopharma d.o.o.<br />
Tel: +386 1 235 51<br />
Ireland 
sanofi-aventis Ireland Ltd. T/A SANOFI 
Tel: +353 (0) 1 403 56<br />
Slovenská republika 
Swixx Biopharma s.r.o. 
Tel: +421 2 208 33 <br />
Ísland 
Vistor hf. 
Sími: +354 535 7 
Suomi/Finland 
Sanofi Oy 
Puh/Tel: + 358 201 200<br />
Italia 
Sanofi S.r.l. 
Tel: +800 536<br />
Sverige 
Sanofi AB 
Tel: +46 (0)8 634 50<br />
Latvija<br />
Swixx Biopharma SIA<br />
Tel: +371 6 616 47<br />
United Kingdom (Northern Ireland) 
sanofi-aventis Ireland Ltd. T/A SANOFI 
Tel: +44 (0) 800 035 2 </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. Der er også links til andre websteder om sjældne sygdomme 
og om, hvordan de behandles.  </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-ed982183c35912e878ca478e2f38304e
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for cerdelga Package Leaflet for language en"
Description: "ePI document Bundle for cerdelga Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-ed982183c35912e878ca478e2f38304e"
* entry[0].resource = composition-en-ed982183c35912e878ca478e2f38304e

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mped982183c35912e878ca478e2f38304e"
* entry[=].resource = mped982183c35912e878ca478e2f38304e
                            
                    
Instance: bundlepackageleaflet-da-ed982183c35912e878ca478e2f38304e
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for cerdelga Package Leaflet for language da"
Description: "ePI document Bundle for cerdelga Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-ed982183c35912e878ca478e2f38304e"
* entry[0].resource = composition-da-ed982183c35912e878ca478e2f38304e

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mped982183c35912e878ca478e2f38304e"
* entry[=].resource = mped982183c35912e878ca478e2f38304e
                            
                    



Instance: mped982183c35912e878ca478e2f38304e
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Cerdelga 84 mg hard capsules"
Description: "Cerdelga 84 mg hard capsules"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/14/974/001 56 capsules"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Cerdelga 84 mg hard capsules"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: ed982183c35912e878ca478e2f38304eListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "cerdelga"

* status = #current
* mode = #working

* title = "List of all ePIs associated with cerdelga"

* subject = Reference(mped982183c35912e878ca478e2f38304e)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#cerdelga "cerdelga"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-ed982183c35912e878ca478e2f38304e) // cerdelga en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-ed982183c35912e878ca478e2f38304e) // cerdelga da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-ed982183c35912e878ca478e2f38304e
InstanceOf: List

* insert ed982183c35912e878ca478e2f38304eListRuleset
    